Poster Abstracts · Clinicians in countries where long-acting injectable cabotegravir and rilpivirine therapy (LAI CAB+RPV) is licensed and being implemented are reporting virological effectiveness in multiple real-world cohorts (RWCs). In randomised-controlled trials · 2024 · 3 citations · Cited by this paper